T-Therapeutics Raises $133M Series B to Push TCR Therapies Into Clinics

Cambridge-based T-Therapeutics closed a $133 million oversubscribed Series B to take its TCR-CD3 bispecific programs in cancer and autoimmunity to clinical proof of concept.